Richard Davies
Direttore/Membro del Consiglio presso ALVOTECH
Patrimonio netto: 16 M $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Robert Bradway | M | 61 | 18 anni | |
Sven Håkan Björklund | M | 68 |
BONE SUPPORT AB
BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | 8 anni |
Erling Lennart Johansson | M | 69 |
BONE SUPPORT AB
BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | 7 anni |
Vilhelm Wessman | M | 54 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 12 anni |
Helga Zharov | F | 57 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 4 anni |
Ann Merchant | F | 59 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 20 anni |
Faysal Kalmoua | M | 48 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 4 anni |
Linda McGoldrick | M | 69 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 2 anni |
Joseph E. McClellan | M | 50 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 5 anni |
David Reese | M | 61 | 19 anni | |
Anil Okay | M | 38 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 6 anni |
Ming Li | M | 47 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 4 anni |
Gertjan Bartlema | M | - |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 2 anni |
Donald Travis Wilson | M | - |
Auregen Biotherapeutics, Inc.
Auregen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auregen Biotherapeutics, Inc. provides biotechnology services. The CEO of the American company is Richard John Davies.
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Joel Morales | M | 46 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 4 anni |
Sigridur Elin Gudlaugsdottir | F | - |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | - |
Esteban Santos | M | 56 | 17 anni | |
Sean Gaskell | M | 42 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 4 anni |
Matthew Busch | M | 50 | 20 anni | |
Lisa Graver | F | 53 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 2 anni |
Robert Eckert | M | 69 | 21 anni | |
Tyler Jacks | M | 63 | 12 anni | |
Benedikt Stefansson | M | - | 2 anni | |
Tomas Ekman | M | 56 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 5 anni |
Árni Harðarson | M | 57 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 2 anni |
Pamela Foulds | M | 55 |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Anthony J. Bolton | M | 74 |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 9 anni |
Simon Robertson | M | 83 |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 9 anni |
Simon Cartmell | M | 64 |
BONE SUPPORT AB
BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | 6 anni |
Giampiero de Luca | M | 70 |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Derek Miller | M | - | 21 anni | |
Jerome Zeldis | M | 74 |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 7 anni |
Matti Jaakko Kesti | M | - |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Selwyn Ho | M | 53 |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 2 anni |
Marcy Zenobi-Wong | F | - |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Richard Davies | M | - |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Frédéric Boder | M | - |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Gilles Lacour | M | - |
Auregen Biotherapeutics SA
Auregen Biotherapeutics SA Packaged SoftwareTechnology Services Auregen Biotherapeutics SA develops three dimensional (3D) bioprinting technology for patients with rare disorders. The company is headquartered in Geneva, Switzerland. | - |
Hugo Thomas Torquil Mackenzie-Smith | M | 52 |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | 15 anni |
Emil Billbäck | M | 54 | 6 anni | |
Helena Brandt | F | 59 | 7 anni | |
Fredrik Lindberg | M | 67 |
Bone Support Incentive AB
Bone Support Incentive AB Real Estate DevelopmentFinance Part of BONESUPPORT HOLDING AB, Bone Support Incentive AB provides real estate services. The company is based in Lund, Sweden. | - |
Lars Åke Alvar Lidgren | M | 81 |
Bone Support Incentive AB
Bone Support Incentive AB Real Estate DevelopmentFinance Part of BONESUPPORT HOLDING AB, Bone Support Incentive AB provides real estate services. The company is based in Lund, Sweden. | - |
Michael Diefenbeck | M | 50 | 7 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Dennis Fenton | M | 72 | 31 anni | |
Pamela Wapnick | F | 58 | 9 anni | |
Marc M. P. de Garidel | M | 66 | 15 anni | |
Paul Eisenberg | M | - | 14 anni | |
Cellia Habita | M | - |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | - |
Tone Kvåle | F | 55 |
BONE SUPPORT AB
BONE SUPPORT AB Medical SpecialtiesHealth Technology BONE SUPPORT AB manufactures orthopedic supplies and equipment. Its products include cerament bone void filler, cerament G with gentamicin, cerament V with vancomycin. The company was founded by Lars Ake Alvar Lidgren in 1999 and is headquartered in Lund, Sweden. | 6 anni |
Michael Kelly | M | 67 | 14 anni | |
David W. Beier | M | 75 | 10 anni | |
Evert Schimmelpennink | M | 52 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 6 anni |
Cynthia Patton | F | 62 | 15 anni | |
John Moriarty | M | 56 | 6 anni | |
Diana McKenzie | F | 59 | 12 anni | |
Gregory L. Tewalt | M | - | - | |
Andrew Knudten | M | - | 17 anni | |
Michael Severino | M | 58 | 10 anni | |
Reem Malki | M | 53 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 1 anni |
Vasant Prakash Gandhi | M | - | 5 anni | |
Craig Shepherd | M | - | 7 anni | |
Rachel Lenington | F | 51 | 10 anni | |
Joseph Newell | M | 54 | 7 anni | |
Thomas Zindrick | M | 65 | 8 anni | |
Nathan Hardy | M | 48 | 10 anni | |
Willard Dere | M | 70 | 11 anni | |
Andreas Grauer | M | 63 | - | |
Marco Renoldi | M | 67 | 3 anni | |
Erin Lavelle | F | 46 | 15 anni | |
Susan Lundeen Smuck | F | 57 | 12 anni | |
Laurie Stelzer | F | 56 | 2 anni | |
Robert Azelby | M | 56 | 5 anni | |
Sean B. W. Martin | M | 61 | - | |
Connie R. Curran | M | 76 | 10 anni | |
Preston Klassen | M | 55 | 7 anni | |
Patricia Cary Sueltz | F | 71 | 2 anni | |
George Morrow | M | 72 | 10 anni | |
David J. Scott | M | 71 | - | |
Rebecca M. Henderson | M | 63 | 11 anni | |
Timothy Martin | M | 55 | 3 anni | |
Sumant Ramachandra | M | 55 | 7 anni | |
Frank Herringer | M | 81 | 15 anni | |
Vance D. Coffman | M | 79 | 9 anni | |
Frederick Gluck | M | 88 | 13 anni | |
Anna Richo | F | 63 | 9 anni | |
Ronald Sugar | M | 75 | 14 anni | |
James Daly | M | 62 | 9 anni | |
Hirofumi Imai | M | 60 |
Alvotech hf
Alvotech hf Pharmaceuticals: MajorHealth Technology Alvotech hf operates as a biotech company. It is focused on the development and manufacture of biosimilar medicines for patients. The company’s products help in treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech was founded by Robert Wessman in 2013 and is headquartered in Reykjavík, Iceland. | 3 anni |
Björn Westberg | M | 62 | - | |
Thomas Johannes W. Dittrich | M | 60 | 4 anni | |
John Smither | M | 71 | 6 anni | |
Jin Long Chen | M | 61 | 4 anni | |
François de Carbonnel | M | 78 | 10 anni | |
Cynthia Flowers | F | 64 | 5 anni | |
William P. Sheridan | M | 69 | 5 anni | |
William Ashton | M | 73 | 16 anni | |
Leonard Schaeffer | M | 78 | 9 anni | |
Steven Galson | M | 67 | - |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 59 | 59.60% |
Lussemburgo | 17 | 17.17% |
Islanda | 17 | 17.17% |
Svezia | 10 | 10.10% |
Svizzera | 8 | 8.08% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Richard Davies
- Contatti personali